What is SELLAS Life Sciences Group Enterprise Value?
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, SELLAS Life Sciences Group's Enterprise Value is €40.60 Mil.
SELLAS Life Sciences Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-33.50 Mil. Therefore, SELLAS Life Sciences Group's EV-to-EBIT ratio for today is -1.21.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SELLAS Life Sciences Group's Enterprise Value
For the Biotechnology subindustry, SELLAS Life Sciences Group's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SELLAS Life Sciences Group's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Enterprise Value distribution charts can be found below:
* The bar in red indicates where SELLAS Life Sciences Group's Enterprise Value falls into.
SELLAS Life Sciences Group Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
SELLAS Life Sciences Group's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SELLAS Life Sciences Group (FRA:RXK3) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
SELLAS Life Sciences Group's EV-to-EBIT for today is
SELLAS Life Sciences Group's current Enterprise Value is €40.60 Mil.
SELLAS Life Sciences Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-33.50 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
SELLAS Life Sciences Group's EV-to-EBITDA for today is:
SELLAS Life Sciences Group's current Enterprise Value is €40.60 Mil.
SELLAS Life Sciences Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-33.50 Mil.
SELLAS Life Sciences Group's current Enterprise Value is €40.60 Mil.
SELLAS Life Sciences Group's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SELLAS Life Sciences Group Enterprise Value Related Terms
Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
SELLAS Life Sciences Group (FRA:RXK3) Business Description
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:RXK3 has been successfully added to your 